What is atypical chronic myeloid leukaemia?
Atypical chronic myeloid leukaemia (aCML) is a rare blood cancer of the bone marrow. The marrow makes too many neutrophils, a type of white blood cell. Many of them look abnormal (dysplastic), and immature white cells spill out into the blood.
Despite its name, aCML is not a form of chronic myeloid leukaemia (CML). Ordinary CML is driven by the Philadelphia chromosome, which creates the BCR::ABL1 fusion gene, and it responds very well to tablets such as imatinib. aCML lacks this gene change, which is why it is often written as “BCR::ABL1-negative”, and those drugs do not work for it.
aCML belongs to a group called myelodysplastic/myeloproliferative neoplasms (MDS/MPN). These diseases share features of two other groups: the marrow overproduces cells, as in myeloproliferative neoplasms, but the cells are also badly formed, as in myelodysplastic syndromes. The latest WHO classification calls the disease “MDS/MPN with neutrophilia”, while the International Consensus Classification keeps the name aCML (Patnaik and Tefferi, 2023).
It mainly affects older adults, and it is a serious condition. It often causes an enlarged spleen, anaemia and tiredness, and it can change into acute myeloid leukaemia (AML). The only treatment that can cure it is an allogeneic stem cell transplant. Other treatments aim to control blood counts and symptoms (Szuber, Orazi and Tefferi, 2024).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Myelodysplastic/myeloproliferative neoplasm with abnormal neutrophils |
| Other names | MDS/MPN with neutrophilia (WHO 2022); aCML, BCR::ABL1-negative |
| How common | Very rare; probably under-recognised in the past |
| Typical age | Usually 60s-70s |
| Philadelphia chromosome | Absent |
| Common gene changes | SETBP1, ASXL1, ETNK1, EZH2, TET2, NRAS/KRAS, SRSF2 |
| Risk of acute leukaemia | About 30-40% |
| Main treatments | Stem cell transplant (curative); hydroxycarbamide, hypomethylating agents, ruxolitinib, interferon |
| Outlook | Serious; median survival about 1-2 years |
2. Types and related conditions
aCML is defined by a pattern of blood and marrow findings rather than by one gene. It must be separated from other conditions that also raise the white cell count.
| Condition | How it differs from aCML |
|---|---|
| Chronic myeloid leukaemia (CML) | BCR::ABL1 present; responds to tyrosine kinase inhibitors |
| Chronic neutrophilic leukaemia (CNL) | Mature neutrophils without dysplasia; usually a CSF3R mutation; few immature cells in the blood |
| Chronic myelomonocytic leukaemia (CMML) | Raised monocyte count |
| MDS/MPN, not otherwise specified | Does not meet criteria for a specific overlap disease |
| Myeloid neoplasms with tyrosine kinase fusions | For example PDGFRA, PDGFRB or FGFR1 rearrangements; often with eosinophilia |
| Reactive neutrophilia | Caused by infection, inflammation or steroids; not a cancer |
Diagnostic features
| Feature | Typical finding in aCML |
|---|---|
| White blood cell count | 13 x 10^9/L or more |
| Immature myeloid cells in the blood | At least 10% of white cells |
| Dysplasia | Prominent abnormal-looking neutrophils (dysgranulopoiesis) |
| Monocytes | Not increased |
| Basophils and eosinophils | Not notably raised |
| Blasts | Fewer than 20% in blood and marrow |
| BCR::ABL1 and other fusions | Absent |
These criteria are summarised from the 2024 review by Szuber, Orazi and Tefferi.
Why it is called “atypical”
When doctors first described the condition, it looked similar to CML in the blood, with a high white count and immature cells. However, it lacked the Philadelphia chromosome and had more dysplasia, so it was labelled “atypical”. We now know that the two diseases are biologically quite different (Fontana, Gambacorti-Passerini and Piazza, 2021).
3. Causes and risk factors
The cause is unknown. The disease arises from acquired mutations in a blood stem cell. These mutations are not inherited.
| Factor | Notes |
|---|---|
| Older age | The main risk factor |
| Previous chemotherapy or radiotherapy | May increase the risk of myeloid neoplasms generally |
Gene changes
| Gene | Notes |
|---|---|
| SETBP1 | One of the most typical mutations; supports the diagnosis |
| ASXL1 | Very common |
| ETNK1 | Less common but fairly specific |
| EZH2, TET2, SRSF2 | Common in MDS/MPN overlap diseases |
| NRAS / KRAS | Activate growth signals; may be targetable |
| CSF3R, JAK2, CBL | Less frequent |
Many of these changes affect signalling pathways such as JAK-STAT and MAPK, which can be targeted by existing drugs (Crisa et al., 2020). Chromosome abnormalities are found in a substantial minority of patients.
4. How does it look
In the blood
| Finding | Description |
|---|---|
| White cell count | High, often well above 13 x 10^9/L |
| Neutrophils | Increased and dysplastic, for example with poorly segmented nuclei or few granules |
| Immature cells | Promyelocytes, myelocytes and metamyelocytes circulating in the blood |
| Haemoglobin | Often low (anaemia) |
| Platelets | Often low |
In the bone marrow
| Finding | Description |
|---|---|
| Cellularity | Very full (hypercellular) |
| Granulocytes | Greatly increased, with dysplasia |
| Blasts | Fewer than 20% |
| Other lines | Red cell and platelet precursors may also be dysplastic |
| Fibrosis | Present in some patients |
On examination
An enlarged spleen is common and may be felt below the left ribs. The liver may also be enlarged.
5. Symptoms
Common symptoms
- Tiredness and weakness from anaemia
- Fullness or discomfort under the left ribs from an enlarged spleen
- Feeling full quickly after small meals
- Weight loss
- Night sweats and low-grade fever
Less common symptoms
| Symptom | Cause |
|---|---|
| Easy bruising or bleeding | Low platelets |
| Frequent infections | Poorly functioning neutrophils |
| Breathlessness | Anaemia |
| Bone pain | Overactive marrow |
| Sudden left-sided pain | Rarely, a splenic infarct |
Some people have no symptoms, and the disease is found on a routine blood test.
When to seek medical advice
See your doctor if you have persistent tiredness, unexplained weight loss, night sweats, frequent infections or discomfort under the left ribs. A simple full blood count is the first step.
6. Diagnosis
| Test | Purpose |
|---|---|
| Full blood count and blood film | Shows high white count, dysplasia and immature cells |
| Bone marrow aspirate and biopsy | Confirms the diagnosis and blast count |
| Cytogenetics | Looks for chromosome changes |
| BCR::ABL1 testing | Excludes CML |
| Next-generation sequencing panel | Detects SETBP1, ASXL1, ETNK1 and other mutations |
| Tests for PDGFRA, PDGFRB, FGFR1 and JAK2 fusions | Excludes other defined diseases |
| Ultrasound of the abdomen | Measures spleen and liver size |
| Other blood tests | Kidney and liver function, uric acid, LDH |
Molecular testing has made the diagnosis more precise than it was when it relied on microscope findings alone (Crisa et al., 2020).
Risk assessment
The Mayo Clinic aCML model gives one point each for age over 67, haemoglobin below 10 g/dL and a TET2 mutation (Patnaik and Tefferi, 2023).
| Risk group | Points | Approximate median survival |
|---|---|---|
| Low risk | 0-1 | About 18 months |
| High risk | 2-3 | About 7 months |
Other high-risk mutations, such as CBL, CEBPA, EZH2, NRAS and U2AF1, have also been identified (Szuber, Orazi and Tefferi, 2024).
7. Treatment
There is no standard treatment proven to change the natural course of aCML, other than transplant. Treatment is guided by risk, symptoms and fitness.
Stem cell transplant
An allogeneic stem cell transplant, using stem cells from a matched donor, is the only potentially curative treatment. It is considered for fitter patients, particularly those with higher-risk disease. It carries significant risks, including graft-versus-host disease and infection.
Medicines to control the disease
| Treatment | Purpose |
|---|---|
| Hydroxycarbamide (hydroxyurea) | Lowers the white cell count and spleen size |
| Hypomethylating agents (azacitidine, decitabine) | Used especially when dysplasia, anaemia or rising blasts are prominent |
| Ruxolitinib | JAK inhibitor; may reduce spleen size and symptoms, particularly with CSF3R or JAK-STAT changes |
| Interferon alfa | Sometimes used, especially in younger patients |
| MEK inhibitors (for example trametinib) | Under study for RAS-mutated disease |
| Clinical trials | Recommended where available |
None of these medicines has been shown to change the long-term course of the disease (Szuber, Orazi and Tefferi, 2024).
Stem cell transplant step by step
| Step | What happens |
|---|---|
| Assessment | Tests of heart, lung, kidney and general fitness; discussion of risks and benefits |
| Finding a donor | A matched brother or sister, an unrelated volunteer, or a half-matched family member |
| Preparing the marrow | Chemotherapy, sometimes with radiotherapy, to clear the diseased marrow |
| Transplant | Donor stem cells are given through a drip, much like a blood transfusion |
| Engraftment | Over 2-4 weeks, the new cells start making blood; infection protection is essential |
| Recovery | Months of close follow-up for infections and graft-versus-host disease |
Before transplant, some patients receive a hypomethylating agent or other treatment to lower the disease burden. The transplant team decides on the type and intensity of preparation based on age and fitness.
Supportive care
| Problem | Treatment |
|---|---|
| Anaemia | Blood transfusions; sometimes erythropoiesis-stimulating agents |
| Low platelets | Platelet transfusions when needed |
| Infections | Prompt antibiotics; vaccinations |
| Painful spleen | Medicines above; rarely splenic radiotherapy or removal |
| Iron overload from transfusions | Iron chelation |
Side effects
| Treatment | Possible side effects |
|---|---|
| Hydroxycarbamide | Low blood counts, mouth ulcers, skin changes |
| Azacitidine or decitabine | Low counts, infections, nausea, injection-site reactions |
| Ruxolitinib | Anaemia, low platelets, infections |
| Stem cell transplant | Infection, graft-versus-host disease, organ damage |
What treatment involves day to day
| Stage | What to expect |
|---|---|
| Tablets | Daily or several times a week, with regular blood counts |
| Hypomethylating agents | Injections or infusions for 5-7 days every 4 weeks |
| Transfusions | Day-unit visits as needed |
| Transplant | Several weeks in hospital and months of close follow-up |
8. Outlook (prognosis)
aCML is a serious disease. Reported median overall survival is about 12-20 months, and transformation to acute myeloid leukaemia occurs in roughly a third of patients (Szuber, Orazi and Tefferi, 2024).
| Factor | Effect on outlook |
|---|---|
| Age over 67 | Poorer survival |
| Haemoglobin below 10 g/dL | Poorer survival |
| TET2 mutation | Poorer survival |
| Rising blasts | Suggests progression towards AML |
| Successful stem cell transplant | The best chance of long-term survival |
Some people live considerably longer than these averages, especially with low-risk features or a successful transplant.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Blood counts every 1-4 weeks | Adjust treatment and spot changes |
| Clinical review | Spleen size, symptoms and infections |
| Repeat bone marrow tests | If counts or blasts change |
| Mutation testing | May be repeated to guide treatment |
| Transplant follow-up | Close monitoring for complications |
10. Living with atypical chronic myeloid leukaemia
- Report fever promptly, as infections can become serious quickly
- Keep vaccinations up to date, after checking which are safe
- Pace yourself and plan rest to manage tiredness
- Eat small, frequent meals if your spleen makes you feel full
- Avoid contact sports if your spleen is enlarged
- Discuss your priorities and wishes with your care team
- Seek support from blood cancer charities and MDS/MPN patient groups
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is aCML the same as CML? | No; it lacks the Philadelphia chromosome and needs different treatment |
| Will imatinib work? | No; imatinib and similar drugs target BCR::ABL1, which aCML does not have |
| Is it inherited? | No; the mutations are acquired |
| Can it be cured? | Only with an allogeneic stem cell transplant |
| Can it turn into acute leukaemia? | Yes, in roughly a third of people |
| Why has the name changed? | WHO now calls it MDS/MPN with neutrophilia to reflect its overlap features |
| Am I too old for a transplant? | Age alone is not the only factor; fitness and other illnesses matter |
| Why is my spleen enlarged? | The spleen fills with excess blood cells and becomes a site of blood production |
| Will I need transfusions? | Many people do at some stage, especially if anaemia worsens |
12. Questions to ask your care team
- What is my risk group, and which mutations does my disease have?
- Am I a candidate for a stem cell transplant?
- Which treatment do you recommend to control my counts and spleen?
- Are there clinical trials I could join?
- How will we know if the disease is progressing?
- What should I do if I develop a fever?
- Who should I contact out of hours?
Resources
- Crisa, E. et al. (2020) ‘Atypical chronic myeloid leukemia: where are we now?’, International Journal of Molecular Sciences, 21(18), 6862.
- Fontana, D., Gambacorti-Passerini, C. and Piazza, R. (2021) ‘Molecular pathogenesis of BCR-ABL-negative atypical chronic myeloid leukemia’, Frontiers in Oncology, 11, 756348.
- Patnaik, M.M. and Tefferi, A. (2023) ‘Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management’, American Journal of Hematology, 98(4), pp. 681-689.
- Szuber, N., Orazi, A. and Tefferi, A. (2024) ‘Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management’, American Journal of Hematology, 99(7), pp. 1360-1387.
- National Cancer Institute (2026) Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.